Experimental study of specific immunotherapy induced by H22 autologous tumor as whole tumor cell vaccine

Biomedicine and Pharmacotherapy

Volumn 63, Issue 6, 2009, Pages 404-408

  Yang, Wei ^a   Guo, Cheng ^a   Liu, Qing guang ^a   Pan, Chengen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Active specific immunotherapy; hIL 2; mGM CSF; Tumor vaccine

Indexed keywords

CHROMIUM 51; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; HEPATOMA CELL; INOCULATION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CHROMIUM RADIOISOTOPES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RATS; SPLEEN; SURVIVAL RATE; TRANSFECTION;

EID: 68649123617     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.08.020     Document Type: Article

References (26)

1. Emens L.A., and Jaffee E.M. Cancer vaccines: an old idea comes of age. Cancer Biol Ther 2 4 Suppl. 1 (2003) S161-S168
2. Armstrong A.C., Eaton D., and Ewing J.C. Cellular vaccine therapy for cancer. Expert Rev Vaccines 1 3 (2002) 303-316
3. Chen Z., Shao J.B., and Wu W. Expression of A, G and B melanoma antigen genes in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 1 4 (2002) 570-573
4. Lin R.Y., Ding J.B., and Wen H. Cloning, homological analysis and construction of Eg95 Xinjiang strain DNA Vaccine. Hepatobiliary Pancreat Dis Int 2 4 (2003) 545-548
5. Ostrand-Rosenberg S., Pulaski B.A., Clements V.K., Qi L., Pipeling M.R., and Hanyok L.A. Cell-based vaccine for the stimulation of immunity to metastatic cancers. Immunol Rev 170 (1999) 101-114
6. Sinkovics J.G., and Horvath J.C. Vaccination against human cancers. Int J Oncol 16 1 (2000) 81-96
7. Jocham D., Richter A., Hoffmann L., Lwig K., Fahlenkamp D., Zakrzewski G., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363 9409 (2004) 594-599
8. Curtis B.M., Williams D.E., Broymeyer H.E., Dunn J., Farrah T., Jeffery E., et al. Enhanced hematopoietic activity of a human granulocyte/ macrophage colon stimulating factor-interleukin 3 fusion protein. Proc Natl Acad Sci USA 88 (1991) 5809
9. Yang W., Pang C.E., and Cao C.X. Active specific immunotherapy of mice bearing liver cancer using novel whole cell tumor vaccine. Chin J Cell Mol Immunol 18 1 (2002) 43-45
10. Bodey B., Siegel S.E., and Kaiser H. Failure of cancer vaccine: the significant limitation of approach to immunotherapy. Anticancer Res 20 (2000) 2665-2676
11. Adler A., Schachter J., Barenholz Y., Bar L.K., Klein T., Korytnaya R., et al. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effect. Cancer Biother 10 4 (1995) 293-306
12. Ge N.L., Ye S.L., Zheng N., Sun R.X., Liu Y.K., and Tang Z.Y. Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines. World J Gastroenterol 9 10 (2003) 2182-2185
13. Chang A.E., Li Q., Jiang G., Sayre D.M., Braun T.M., and Redman B.G. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21 5 (2003) 884-890
14. Antonia S.J., Seigne J., Diaz J., Muro-Cacho C., Extermann M., Farmelo M.J., et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167 5 (2002) 1995-2000
15. Lotem M., Shiloni E., Pappo I., Drize O., Hamburger T., Weitzen R., et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 90 4 (2004) 773-780
16. Weinreich D.M., and Rosenberg S.A. Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to lpha-interferon or low-dose interleukin-2. J Immunother 25 2 (2002) 185-187
17. Jager D., Jager E., and Knuth A. Vaccination for malignant melanoma: recent developments. Oncology 60 1 (2001) 1-7
18. Belli F., Arienti F., Sulesuso J., Clemente C., Mascheroni L., Cattelan A., et al. Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: evalution of efficacy and tolerability. Cancer Immunol Immunother 44 2 (1997) 197-203
19. Leong S.P., Encers Z.P., and Zhou Y.M. Recombinant human granulocyte macrophage colony-stimulating factor(rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 22 2 (1999) 166-174
20. Ai K.F., Chen D.S., and Hwang L.H. Curative potential of GM-CSF-secreting tumor cell vaccines on established orthotopic liver tumors: mechanisms for the superior antitumor activity of live tumor cell vaccines. J Biomed Sci 11 2 (2004) 228-238
21. Pardoll D. Therapeutic vaccination for cancer. Clin Immunol 95 1 (2000) s44-s62
22. Lee S.G., Heo D.S., Yoon S.J., Jee Y.S., Kang J.O., Kim K., et al. Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response. Anticancer Res 20 (2000) 2681-2686
23. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levistsky H. The central role of CD4+T cells in the antitumor immune response. J Exp Med 188 12 (1998) 2357-2368
24. Blum H.E. Molecular therapy and prevention of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2 1 (2003) 23-27
25. Sun X.Y., Wu Z.D., and Hu J.B. Suicide gene therapy of hepatocellular carcinoma and delivery procedure and route of therapeutic gene in vitro. Hepatobiliary Pancreat Dis Int 1 3 (2002) 373-377
26. Huang L., and Ohno T. Protective antitumor immunity induced by fixed tumor cells in combination with adjuvant in a murine hepatoma model. Cancer Lett 202 2 (2003) 153-159